Cryoport, Inc.

NasdaqCM:CYRX 株式レポート

時価総額：US$806.4m

Cryoport 将来の成長

Future 基準チェック /06

Cryoport利益と収益がそれぞれ年間13.7%と9.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-9.5% 16.7%なると予測されています。

主要情報

13.7%

収益成長率

16.69%

EPS成長率

Life Sciences 収益成長17.0%
収益成長率9.5%
将来の株主資本利益率-9.55%
アナリストカバレッジ

Good

最終更新日08 Jun 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 26

CYRX: Bioservices Demand And Service Mix Will Drive Future Upside

The analyst price target for Cryoport has been raised from $16.00 to about $19.93. Analysts cite stronger expected revenue growth, slightly higher margin assumptions, and a modestly lower future P/E multiple as key factors behind their updated view.
ナラティブの更新 • Jun 12

CYRX: Differentiated Bioservices And Regulatory Support Will Shape Balanced Forward Outlook

Cryoport's analyst price target has moved up by $2 to $15.61, with analysts pointing to stronger appreciation for its differentiated bioservices offering, higher perceived revenue visibility and margin potential, and ongoing regulatory and funding support for growth as key drivers of their updated views. Analyst Commentary Recent research updates have centered on Cryoport's bioservices operations, with several firms revisiting their valuation frameworks after site visits and a review of end market conditions.
ナラティブの更新 • May 29

CYRX: Elevated Expectations For Service Group Margins Will Challenge Execution

Analysts have lifted their price targets on Cryoport, prompting an updated fair value estimate from $9.51 to $11.00, citing stronger revenue visibility, improved margin expectations through 2028, and a broad base of commercial and clinical customers as key supports for the stock. Analyst Commentary Recent Street research has leaned constructive on Cryoport, with several firms lifting price targets and highlighting the company’s revenue visibility, margin profile through 2028, and breadth of commercial and clinical relationships.
ナラティブの更新 • May 03

CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside

Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.
ナラティブの更新 • Apr 19

CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook

Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.
ナラティブの更新 • Apr 03

CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns

Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.
ナラティブの更新 • Mar 20

CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential

Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.
ナラティブの更新 • Mar 04

CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential

Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).
ナラティブの更新 • Feb 18

CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects

Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).
ナラティブの更新 • Feb 04

CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects

Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).
ナラティブの更新 • Jan 21

CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside

Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.
ナラティブの更新 • Jan 06

CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects

Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.
ナラティブの更新 • Dec 20

CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects

Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.
ナラティブの更新 • Dec 06

CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside

Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.
ナラティブの更新 • Nov 22

CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery

The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.
ナラティブの更新 • Nov 06

CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound

Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.
ナラティブの更新 • Aug 07

Cold Chain Expansion Will Support Cell And Gene Therapies

Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.
分析記事 • Jul 22

Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...
分析記事 • May 30

Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable

Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...
分析記事 • Apr 09

Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
User avatar
新しいナラティブ • Mar 30

New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply

Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.
分析記事 • Mar 06

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price

Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...
分析記事 • Feb 22

Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower

Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...
分析記事 • Dec 03

Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)

You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...
分析記事 • Nov 06

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Aug 09

The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More

Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...
分析記事 • Jul 22

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Jun 25

Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Cryoport, Inc. ( NASDAQ:CYRX ) share price has dived 28% in the last thirty...

業績と収益の成長予測

NasdaqCM:CYRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028234-2820434
12/31/2027213-33-999
12/31/2026194-39-25-59
3/31/2026183-45-26-1N/A
12/31/2025176-42-28-9N/A
9/30/2025172-48-35-15N/A
6/30/2025166-38-38-17N/A
3/31/2025161-104-38-17N/A
12/31/2024157-113-38-16N/A
9/30/2024173-158-36-8N/A
6/30/2024190-175-45-11N/A
3/31/2024208-117-46-7N/A
12/31/2023169-93-46-1N/A
9/30/2023236-55-410N/A
6/30/2023241-47-323N/A
3/31/2023248-38-290N/A
12/31/2022237-45-26-2N/A
9/30/2022233-296-27-3N/A
6/30/2022230-297-235N/A
3/31/2022222-293-1215N/A
12/31/2021223-284-178N/A
9/30/2021215-76-25-4N/A
6/30/2021169-78-32-18N/A
3/31/2021122-77-34-22N/A
12/31/202079-75-25-15N/A
9/30/202040-22-11-4N/A
6/30/202038-23-60N/A
3/31/202037-20-50N/A
12/31/201934-18N/A-1N/A
9/30/201930-20N/A-2N/A
6/30/201926-9N/A-2N/A
3/31/201922-9N/A-2N/A
12/31/201820-10N/A-3N/A
9/30/201817-10N/A-4N/A
6/30/201815-9N/A-5N/A
3/31/201813-9N/A-4N/A
12/31/201712-8N/A-4N/A
9/30/201711-10N/A-3N/A
6/30/201710-10N/A-4N/A
3/31/20179-12N/A-5N/A
12/31/20168-13N/A-6N/A
9/30/20167-12N/A-6N/A
6/30/20166-12N/A-6N/A
3/31/20166-15N/A-6N/A
12/31/20156-16N/A-6N/A
9/30/20155-15N/A-5N/A
6/30/20154-16N/A-5N/A

アナリストによる今後の成長予測

収入対貯蓄率: CYRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYRX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CYRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYRXの収益 ( 9.5% ) US市場 ( 12.7% ) よりも低い成長が予測されています。

高い収益成長: CYRXの収益 ( 9.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CYRX 3 年以内に赤字になると予測されています。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/28 04:11
終値2026/06/26 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cryoport, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14

アナリスト機関
Paul KnightBrean Capital Historical (Janney Montgomery)
Andrew D'SilvaB. Riley Securities, Inc.
Yuan ZhiB. Riley Securities, Inc.